Literature DB >> 22315403

Essential requirement for β-arrestin2 in mouse intestinal tumors with elevated Wnt signaling.

Caroline Bonnans1, Maud Flacelière, Fanny Grillet, Christelle Dantec, Jean-Pierre Desvignes, Julie Pannequin, Dany Severac, Emeric Dubois, Frédéric Bibeau, Virginie Escriou, Philippe Crespy, Laurent Journot, Frédéric Hollande, Dominique Joubert.   

Abstract

β-Arrestins (Arrb) participate in the regulation of multiple signaling pathways, including Wnt/β-catenin, the major actor in human colorectal cancer initiation. To better understand the roles of Arrb in intestinal tumorigenesis, a reverse genetic approach (Arrb(-/-)) and in vivo siRNA treatment were used in Apc(Δ14/+) mice. Mice with Arrb2 depletion (knockout and siRNA) developed only 33% of the tumors detected in their Arrb2-WT littermates, whereas Arrb1 depletion remained without significant effect. These remaining tumors grow normally and are essentially Arrb2-independent. Unsupervised hierarchical clustering analysis showed that they clustered with 25% of Apc(Δ14/+);Arrb2(+/+) tumors. Genes overexpressed in this subset reflect a high interaction with the immune system, whereas those overexpressed in Arrb2-dependent tumors are predominantly involved in Wnt signaling, cell adhesion, migration, and extracellular matrix remodeling. The involvement of Arrb2 in intestinal tumor development via the regulation of the Wnt pathway is supported by ex vivo and in vitro experiments using either tumors from Apc(Δ14/+) mice or murine Apc(Min/+) cells. Indeed, Arrb2 siRNAs decreased the expression of Wnt target genes in cells isolated from 12 of 18 tumors from Apc(Δ14/+) mice. In Apc(Min/+) cells, Arrb2 siRNAs completely reversed the increased Wnt activity and colony formation in soft agar induced by Apc siRNA treatment, whereas they did not affect these parameters in basal conditions or in cells expressing constitutively active β-catenin. We demonstrate that Arrb2 is essential for the initiation and growth of intestinal tumors displaying elevated Wnt pathway activity and identify a previously unsuspected molecular heterogeneity among tumors induced by truncating Apc mutations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315403      PMCID: PMC3286958          DOI: 10.1073/pnas.1109457109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.

Authors:  Partha S Ray; Jinhua Wang; Ying Qu; Myung-Shin Sim; Jaime Shamonki; Sanjay P Bagaria; Xing Ye; Bingya Liu; David Elashoff; Dave S Hoon; Michael A Walter; John W Martens; Andrea L Richardson; Armando E Giuliano; Xiaojiang Cui
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

2.  How to make siRNA lipoplexes efficient? Add a DNA cargo.

Authors:  Hervé Rhinn; Céline Largeau; Pascal Bigey; René Lai Kuen; Magali Richard; Daniel Scherman; Virginie Escriou
Journal:  Biochim Biophys Acta       Date:  2009-04

3.  Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.

Authors:  Jürgen Deka; Norbert Wiedemann; Pascale Anderle; Fabienne Murphy-Seiler; Jennyfer Bultinck; Sven Eyckerman; Jean-Christophe Stehle; Sylvie André; Nathalie Vilain; Olav Zilian; Sylvie Robine; Mauro Delorenzi; Konrad Basler; Michel Aguet
Journal:  Cancer Res       Date:  2010-08-03       Impact factor: 12.701

4.  Symplekin promotes tumorigenicity by up-regulating claudin-2 expression.

Authors:  Michael Buchert; Marina Papin; Caroline Bonnans; Charbel Darido; Warren S Raye; Véronique Garambois; André Pélegrin; Jean-François Bourgaux; Julie Pannequin; Dominique Joubert; Frédéric Hollande
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-25       Impact factor: 11.205

5.  Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer.

Authors:  Ciara Metcalfe; Ashraf E K Ibrahim; Michael Graeb; Marc de la Roche; Thomas Schwarz-Romond; Marc Fiedler; Douglas J Winton; Anthony Corfield; Mariann Bienz
Journal:  Cancer Res       Date:  2010-07-27       Impact factor: 12.701

6.  Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells.

Authors:  Timothy T Li; Mistre Alemayehu; Adel I Aziziyeh; Cynthia Pape; Macarena Pampillo; Lynne-Marie Postovit; Gordon B Mills; Andy V Babwah; Moshmi Bhattacharya
Journal:  Mol Cancer Res       Date:  2009-07       Impact factor: 5.852

Review 7.  Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways.

Authors:  Jeffrey J Kovacs; Makoto R Hara; Chandra L Davenport; Jihee Kim; Robert J Lefkowitz
Journal:  Dev Cell       Date:  2009-10       Impact factor: 12.270

8.  Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium.

Authors:  François Gerbe; Johan H van Es; Leila Makrini; Bénédicte Brulin; Georg Mellitzer; Sylvie Robine; Béatrice Romagnolo; Noah F Shroyer; Jean-François Bourgaux; Christine Pignodel; Hans Clevers; Philippe Jay
Journal:  J Cell Biol       Date:  2011-03-07       Impact factor: 10.539

9.  Complete deletion of Apc results in severe polyposis in mice.

Authors:  A F Cheung; A M Carter; K K Kostova; J F Woodruff; D Crowley; R T Bronson; K M Haigis; T Jacks
Journal:  Oncogene       Date:  2009-12-14       Impact factor: 9.867

10.  {beta}-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation.

Authors:  Seungkirl Ahn; Jihee Kim; Makoto R Hara; Xiu-Rong Ren; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2009-01-26       Impact factor: 5.157

View more
  22 in total

1.  The polarity protein VANG-1 antagonizes Wnt signaling by facilitating Frizzled endocytosis.

Authors:  Chun-Wei He; Chien-Po Liao; Chung-Kuan Chen; Jérôme Teulière; Chun-Hao Chen; Chun-Liang Pan
Journal:  Development       Date:  2018-12-17       Impact factor: 6.868

Review 2.  Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Authors:  Louis M Luttrell; Stuart Maudsley; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

3.  Delineation of a conserved arrestin-biased signaling repertoire in vivo.

Authors:  Stuart Maudsley; Bronwen Martin; Diane Gesty-Palmer; Huey Cheung; Calvin Johnson; Shamit Patel; Kevin G Becker; William H Wood; Yongqing Zhang; Elin Lehrmann; Louis M Luttrell
Journal:  Mol Pharmacol       Date:  2015-01-30       Impact factor: 4.436

4.  β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression.

Authors:  Xuanxuan Jing; Hui Zhang; Jing Hu; Peng Su; Wei Zhang; Ming Jia; Hongxia Cheng; Weiwei Li; Gengyin Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

Authors:  Anja Lachenmayer; Clara Alsinet; Radoslav Savic; Laia Cabellos; Sara Toffanin; Yujin Hoshida; Augusto Villanueva; Beatriz Minguez; Philippa Newell; Hung-Wen Tsai; Jordi Barretina; Swan Thung; Stephen C Ward; Jordi Bruix; Vincenzo Mazzaferro; Myron Schwartz; Scott L Friedman; Josep M Llovet
Journal:  Clin Cancer Res       Date:  2012-07-18       Impact factor: 12.531

6.  Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy.

Authors:  Grazyna Adamus; Rachel Champaigne; Sufang Yang
Journal:  Clin Immunol       Date:  2019-11-23       Impact factor: 3.969

7.  Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.

Authors:  Huairui Yuan; Ni Li; Da Fu; Jiale Ren; Jingyi Hui; Junjie Peng; Yongfeng Liu; Tong Qiu; Min Jiang; Qiang Pan; Ying Han; Xiaoming Wang; Qintong Li; Jun Qin
Journal:  J Clin Invest       Date:  2017-08-21       Impact factor: 14.808

8.  β-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling.

Authors:  Yidong Yang; Yunwei Guo; Siwei Tan; Bilun Ke; Jin Tao; Huiling Liu; Jie Jiang; Jianning Chen; Guihua Chen; Bin Wu
Journal:  Nat Commun       Date:  2015-06-16       Impact factor: 14.919

9.  SUMOylation attenuates human β-arrestin 2 inhibition of IL-1R/TRAF6 signaling.

Authors:  Ning Xiao; Hui Li; Wenhan Mei; Jinke Cheng
Journal:  J Biol Chem       Date:  2014-11-25       Impact factor: 5.157

10.  Bidirectional KCNQ1:β-catenin interaction drives colorectal cancer cell differentiation.

Authors:  Raphael Rapetti-Mauss; Viviana Bustos; Warren Thomas; Jean McBryan; Harry Harvey; Natalia Lajczak; Stephen F Madden; Bernard Pellissier; Franck Borgese; Olivier Soriani; Brian J Harvey
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.